BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,594,920 | +14.5% | 649,000 | +13.9% | 2.61% | +17.0% |
Q2 2023 | $4,012,800 | +14.7% | 570,000 | +35.9% | 2.23% | -7.7% |
Q1 2023 | $3,498,630 | +143.8% | 419,500 | +235.6% | 2.41% | +70.2% |
Q4 2022 | $1,435,000 | +62.7% | 125,000 | +78.6% | 1.42% | +56.7% |
Q3 2022 | $882,000 | +264.5% | 70,000 | +300.0% | 0.90% | +1174.6% |
Q4 2021 | $242,000 | – | 17,500 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |